The efficacy and safety of oral propafenone for the prevention of atrial fibrillation (AF) were tested in a group of 293 patients who underwent coronary artery bypass grafting. Patients were randomized to placebo or 1 of 2 doses of propafenone. Patients treated with propafenone 675 mg/day compared with placebo had a nonsignificantly reduced incidence of AF and did not have a reduction in length of stay. Adverse events and discontinuations for untoward events were equal among the 3 groups.
Copyright 2004 Excerpta Medica, Inc.